CD1D and B-cell non-Hodgkin lymphoma: A similar scenario exists for multiple myeloma and B-cell lymphoma, since CD1d is downregulated and associated with poor outcomes in contrast to higher CD1d expression levels in PBMCs from healthy individuals (181).